Skip to main content
. Author manuscript; available in PMC: 2017 Nov 24.
Published in final edited form as: JAMA Neurol. 2016 Apr;73(4):447–455. doi: 10.1001/jamaneurol.2015.4885

Table 2. Model for MRC Scale Decline in Trial-Relevant Populationa.

Factor Estimate (95% CI) P Value P Value for Heterogeneity/Interaction vs Reference Category
Estimates of Baseline and Decline
Baseline, aged 65 y
    MM 53.19 (47.82 to 58.55) NA NA
    MV 57.88 (53.85 to 61.90) NA   .17
    VV 50.89 (45.60 to 56.18) NA   .55
    Per 10 y older at enrollment −4.12 (−7.14 to −1.10)   .008 NA
Decline, per d
    MM −1.90 (−2.36 to −1.45) <.001 NA
    MV −0.36 (−0.83 to 0.11) <.001 <.001
    VV −0.76 (−1.24 to −0.28) <.001 <.001
Estimates of Individual Variability
MM
    Baseline 17.17 (13.31 to 22.17) NA NA
    Decline   1.36 (0.95 to 1.95) NA NA
    Correlation (baseline, decline)   0.38 (0.00 to 0.66) NA NA
    Residual error 12.80 (10.91 to 15.02) NA NA
Non-MM
    Baseline 14.75 (12.52 to 17.37) NA NA
    Decline   0.33 (0.24 to 0.46) NA NA
    Correlation (baseline, decline)   0.24 (−0.02 to 0.47) NA NA
    Residual error   9.20 (8.57 to 9.87) NA NA

Abbreviations: MRC, Medical Research Council; NA, not applicable.

a

Model includes 824 measurements from 154 patients with sporadic Creutzfeldt-Jakob disease and patients with fast IPD in stratum 1 with MRC Scale of 5 or greater at enrollment. Reference category aged 65 years, MM.